Endomorphin-1 & Endomorphin-2 Dosage Calculator

Endomorphin-1 & Endomorphin-2 Pharmacokinetics

Endomorphin-1 & Endomorphin-2 Dosing Protocol

Note: Endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and Endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) are endogenous opioid tetrapeptides and the most selective mu-opioid receptor agonists identified in mammalian tissue. First described by Zadina et al. in 1997, they remain research-only compounds with no approved clinical applications. Their extremely short plasma half-life (minutes) severely limits therapeutic utility in native form, though stabilized analogs (e.g., CYT-1010) have entered early clinical testing. Both peptides are subject to rapid degradation by dipeptidyl peptidase IV (DPP-IV) and aminopeptidases. Dosing values shown are estimates based on preclinical intracerebroventricular and intrathecal rodent studies and should not be interpreted as human dosing guidance. These peptides carry opioid-class risks including respiratory depression, dependence, and tolerance development. Endomorphins are presented here strictly for academic and research reference.

About Endomorphin-1 & Endomorphin-2

Endomorphin-1 and Endomorphin-2 are a pair of endogenous opioid tetrapeptides discovered in 1997 by James Zadina and colleagues, isolated from bovine and human brain tissue. They are the first and only endogenous peptides identified with high affinity and extraordinary selectivity for the mu-opioid receptor (MOR). Before their discovery, endogenous ligands had been identified for delta (enkephalins) and kappa (dynorphins) opioid receptors, but the endogenous mu-receptor ligand remained elusive. Endomorphin-1 (EM-1; Tyr-Pro-Trp-Phe-NH2) and Endomorphin-2 (EM-2; Tyr-Pro-Phe-Phe-NH2) differ only at the third amino acid position — tryptophan in EM-1 versus phenylalanine in EM-2 — yet this single substitution produces distinct pharmacological profiles. EM-1 displays a binding affinity (Ki) of approximately 360 pM for the mu-receptor with 4,000-fold selectivity over delta and 15,000-fold over kappa receptors. EM-2 binds with a Ki of approximately 690 pM, showing 13,400-fold mu/delta selectivity and 7,600-fold mu/kappa selectivity, making it even more mu-selective than EM-1. Both peptides are C-terminally amidated, a modification critical for receptor binding and enzymatic stability. In the central nervous system, EM-1 is predominantly localized in the nucleus accumbens, cortex, amygdala, thalamus, hypothalamus, striatum, and dorsal root ganglia, while EM-2 is concentrated in the spinal cord and lower brainstem, suggesting complementary roles in supraspinal versus spinal pain modulation. In rodent antinociception assays, EM-1 is approximately 3-fold more potent than EM-2 in supraspinal (intracerebroventricular) administration, producing potent dose-dependent analgesia in both hot-plate and tail-flick tests that is fully reversed by naloxone. At the spinal level, EM-2 engages additional descending pathways involving dynorphin A and met-enkephalin, indicating a more complex analgesic mechanism than EM-1. Beyond pain, endomorphins modulate cardiovascular function (EM-2 produces hypotension and bradycardia via nucleus tractus solitarius activation), immune regulation (anti-inflammatory effects in both acute and chronic peripheral inflammation models), reward and motivation, stress responses, and neuroendocrine function. A major limitation of native endomorphins is their extremely rapid enzymatic degradation — plasma half-life is estimated at 2-8 minutes — primarily by dipeptidyl peptidase IV (DPP-IV) cleaving the Tyr-Pro bond. However, degradation in cerebrospinal fluid proceeds more slowly, requiring over 2 hours for complete inactivation. This instability has driven extensive medicinal chemistry efforts to create stabilized analogs. Modified endomorphin analogs incorporating D-amino acids, N-methylation, or lipid conjugation have achieved dramatically improved metabolic stability, blood-brain barrier penetration, and prolonged analgesia with reduced side effects compared to morphine in preclinical models. One such analog, CYT-1010 (a cyclized EM-1 derivative), completed a Phase I clinical trial demonstrating significant analgesia versus baseline in healthy volunteers with no observed respiratory depression. Preclinical evidence suggests endomorphin-based analogs may produce less tolerance, lower abuse liability, reduced respiratory depression, and less constipation compared to morphine at equianalgesic doses, positioning them as a potential next-generation opioid analgesic platform.

Frequently Asked Questions